Sonoma Pharmaceuticals Total Assets Growth & History (SNOA)
Sonoma Pharmaceuticals's total assets was $14.0M for fiscal 2026.
View full Sonoma Pharmaceuticals company overviewSonoma Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $14.0M | $267,000 | +1.95% |
| 2025 | 2025-03-31 | $13.7M | −$1.0M | −7.10% |
| 2024 | 2024-03-31 | $14.7M | −$1.5M | −9.19% |
| 2023 | 2023-03-31 | $16.2M | −$2.6M | −13.87% |
| 2022 | 2022-03-31 | $18.8M | $3.9M | +25.74% |
| 2021 | 2021-03-31 | $15.0M | $426,000 | +2.93% |
| 2020 | 2020-03-31 | $14.6M | $113,000 | +0.78% |
| 2019 | 2019-03-31 | $14.4M | −$4.8M | −24.77% |
| 2018 | 2018-03-31 | $19.2M | −$6.3M | −24.56% |
| 2017 | 2017-03-31 | $25.5M | $11.7M | +84.45% |
| 2016 | 2016-03-31 | $13.8M | −$1.2M | −8.27% |
| 2015 | 2015-03-31 | $15.0M | −$5.7M | −27.62% |
| 2014 | 2014-03-31 | $20.8M | $8.2M | +65.47% |
| 2013 | 2013-03-31 | $12.6M | $4.7M | +60.31% |
| 2012 | 2012-03-31 | $7.8M | −$826,000 | −9.53% |
| 2011 | 2011-03-31 | $8.7M | — | — |
Sonoma Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $18.1M | $3.5M | +24.07% |
| Q4 2026 | 2026-03-31 | $14.0M | $267,000 | +1.95% |
| Q3 2026 | 2025-12-31 | $13.6M | −$45,000 | −0.33% |
| Q2 2026 | 2025-09-30 | $13.9M | $171,000 | +1.25% |
| Q1 2026 | 2025-06-30 | $14.6M | $921,000 | +6.74% |
| Q4 2025 | 2025-03-31 | $13.7M | −$1.0M | −7.10% |
| Q3 2025 | 2024-12-31 | $13.7M | −$950,000 | −6.50% |
| Q2 2025 | 2024-09-30 | $13.7M | $50,000 | +0.37% |
| Q1 2025 | 2024-06-30 | $13.7M | −$2.2M | −13.97% |
| Q4 2024 | 2024-03-31 | $14.7M | −$1.5M | −9.19% |
| Q3 2024 | 2023-12-31 | $14.6M | $690,000 | +4.95% |
| Q2 2024 | 2023-09-30 | $13.6M | −$1.3M | −8.87% |
| Q1 2024 | 2023-06-30 | $15.9M | −$1.3M | −7.37% |
| Q4 2023 | 2023-03-31 | $16.2M | −$2.6M | −13.87% |
| Q3 2023 | 2022-12-31 | $13.9M | −$5.4M | −28.01% |
| Q2 2023 | 2022-09-30 | $15.0M | −$4.9M | −24.54% |
| Q1 2023 | 2022-06-30 | $17.2M | $3.0M | +21.51% |
| Q4 2022 | 2022-03-31 | $18.8M | $3.9M | +25.74% |
| Q3 2022 | 2021-12-31 | $19.3M | $1.1M | +6.12% |
| Q2 2022 | 2021-09-30 | $19.8M | $1.7M | +9.28% |
| Q1 2022 | 2021-06-30 | $14.1M | −$4.0M | −21.91% |
| Q4 2021 | 2021-03-31 | $15.0M | $426,000 | +2.93% |
| Q3 2021 | 2020-12-31 | $18.2M | $1.7M | +10.52% |
| Q2 2021 | 2020-09-30 | $18.1M | $2.0M | +12.39% |
| Q1 2021 | 2020-06-30 | $18.1M | $1.2M | +6.89% |
| Q4 2020 | 2020-03-31 | $14.6M | $113,000 | +0.78% |
| Q3 2020 | 2019-12-31 | $16.5M | −$549,000 | −3.22% |
| Q2 2020 | 2019-09-30 | $16.1M | $1.8M | +12.52% |
| Q1 2020 | 2019-06-30 | $16.9M | $285,000 | +1.71% |
| Q4 2019 | 2019-03-31 | $14.4M | −$4.8M | −24.77% |
| Q3 2019 | 2018-12-31 | $17.0M | −$1.3M | −7.14% |
| Q2 2019 | 2018-09-30 | $14.3M | −$5.8M | −28.80% |
| Q1 2019 | 2018-06-30 | $16.6M | −$5.8M | −25.82% |
| Q4 2018 | 2018-03-31 | $19.2M | −$6.3M | −24.56% |
| Q3 2018 | 2017-12-31 | $18.4M | −$9.2M | −33.27% |
| Q2 2018 | 2017-09-30 | $20.2M | $10.9M | +118.08% |
| Q1 2018 | 2017-06-30 | $22.4M | $11.1M | +98.07% |
| Q4 2017 | 2017-03-31 | $25.5M | $11.7M | +84.45% |
| Q3 2017 | 2016-12-31 | $27.5M | $15.4M | +127.37% |
| Q2 2017 | 2016-09-30 | $9.2M | −$4.3M | −31.97% |
| Q1 2017 | 2016-06-30 | $11.3M | −$2.9M | −20.32% |
| Q4 2016 | 2016-03-31 | $13.8M | −$1.2M | −8.27% |
| Q3 2016 | 2015-12-31 | $12.1M | $264,000 | +2.23% |
| Q2 2016 | 2015-09-30 | $13.6M | −$4.8M | −26.15% |
| Q1 2016 | 2015-06-30 | $14.2M | −$5.7M | −28.54% |
| Q4 2015 | 2015-03-31 | $15.0M | −$5.7M | −27.62% |
| Q3 2015 | 2014-12-31 | $11.8M | $2.0M | +20.23% |
| Q2 2015 | 2014-09-30 | $18.4M | $9.5M | +107.09% |
| Q1 2015 | 2014-06-30 | $19.9M | $9.3M | +87.87% |
| Q4 2014 | 2014-03-31 | $20.8M | $8.2M | +65.47% |
| Q3 2014 | 2013-12-31 | $9.8M | −$2.0M | −16.80% |
| Q2 2014 | 2013-09-30 | $8.9M | −$4.5M | −33.68% |
| Q1 2014 | 2013-06-30 | $10.6M | $888,000 | +9.16% |
| Q4 2013 | 2013-03-31 | $12.6M | $4.7M | +60.31% |
| Q3 2013 | 2012-12-31 | $11.8M | $2.8M | +31.72% |
| Q2 2013 | 2012-09-30 | $13.4M | $5.6M | +72.51% |
| Q1 2013 | 2012-06-30 | $9.7M | $483,000 | +5.24% |
| Q4 2012 | 2012-03-31 | $7.8M | −$826,000 | −9.53% |
| Q3 2012 | 2011-12-31 | $9.0M | — | — |
| Q2 2012 | 2011-09-30 | $7.8M | — | — |
| Q1 2012 | 2011-06-30 | $9.2M | — | — |
| Q4 2011 | 2011-03-31 | $8.7M | — | — |
Sonoma Pharmaceuticals total assets trends
Over the last five fiscal years, Sonoma Pharmaceuticals's total assets decreased from $15.0M to $14.0M, a change of −$1.0M. The latest reported quarter, Q1 2027, shows $18.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sonoma Pharmaceuticals source filings ↗